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Abstract
Background
Data on genetic variants that can predict follow-up cardiovascular events are highly limited,
particularly for Asians. The aim of this study was to validate the effects of two variants in
FLT1 and 9p21 on long-term cardiovascular outcomes in high-risk Korean patients.
Methods
We examined the prognostic values of the rs9508025 and rs1333049 variants that were
found to be associated with coronary artery disease (CAD) risk in a previous Korean
genome-wide association study. A total of 2693 patients (mean age: 55.2 years; male:
55.2%) with CAD or its risk factors at baseline were enrolled and followed for major adverse
cardiac events (MACE).
Results
During the mean follow-up of 8.8 years, 15.4% of the patients experienced MACE. Kaplan-
Meier curves showed that MACE-free survival was different according to the genotype of
rs9508025 (log rank p = 0.02), whereas rs1333049 genotype did not correlate with the
prognosis. Multivariate Cox proportional hazard analysis showed that C-allele of
rs9508025 was significantly associated with a high rate of MACE, while rs1333049 was
not. Further analyses demonstrated that the association of the rs9508025 variant with
MACE was mainly due to its relation to coronary revascularization, which was also associ-
ated with the rs1333049 variant. In an additional analysis, rs9508025 was found to be an
independent determinant of the outcome only in the subgroup with history of CAD.
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Conclusions
rs9508025 in FLT1 was significantly associated with long-term cardiovascular events, par-
ticularly in patients with prior CAD. The association of rs1333049 in 9p21 was not
significant.
Introduction
In order to predict the risk for atherosclerotic cardiovascular events, one of the most common
causes of mortality and morbidity around the world, numerous studies have been performed.
An accurate risk assessment using effectivemarkers can be helpful for preventing cardiovascu-
lar events [1]. For instance, adding the influence of single nucleotide polymorphisms (SNPs) to
the conventional risk calculation has been used for improving risk discrimination [2, 3].
Atherosclerotic cardiovascular disease is known to be under strong genetic influence. For
decades, significant relationship between several SNPs in candidate genes and cardiovascular
risk was reported by association studies [4]. In addition, with the progression of high-through-
put technology and cost reductions, large-scale genome-wide association studies (GWAS)
revealedmultiple disease-related loci and pathways, provided researchers with new pathophys-
iological insights, and risk markers as well [5]. Genetic variants linked to traditional risk factors
are found among dozens of validated risk variants. However, many of them, such as those in
9p21, are not related to the known risk factors [6].
To date, most genetic marker investigation have been based on association studies in a
cross-sectionalmanner. Conversely, several studies that searched for the genetic determinants
associated with the follow-up outcome were conducted. Among the individuals in need of pri-
mary cardiovascular prevention, a variant at 3q22.3 [7] and another one in eNOS [8] were
identified as having predictive value in longitudinal studies. In patients that already experi-
enced cardiovascular events, genetic variants in lipoprotein-associated genes [7, 9–11], 9p21
[12], and ABO blood group system [13] were found to have prognostic values. However, data
regarding variants validated for predicting long-term cardiovascular outcome are still
extremely limited. In Asians, a few association studies have identified several variants related to
the risk of coronary artery disease [14, 15]. However, studies on the variants predicting cardio-
vascular risk in individuals of Asian ethnicities had several limitations: 1) they have been far
less studied than the individuals of European ancestry, 2) among the studies on Asians, the
investigated variants that were predictive of follow-up outcomes were very rare, and 3) the fol-
low-up duration for Asian studies performed thus far has not been long enough for valid con-
clusions regarding the association with the variants [16, 17].
The aims of this study were to validate the association of two variants on the long-term car-
diovascular outcome in high-risk Korean patients, with or without coronary artery disease
(CAD). To identify variants predictive of long-term cardiovascular outcomes, two candidate
SNPs were selected. One of the candidates was rs9508025 in FLT1, because its p value was
more significant than that of SORT1 or PDGFD in Korean GWAS [18], although it was not
very strong. Furthermore, it was replicated in the Japanese population, another East Asian eth-
nicity [18]. The loci of SORT1 and PDGFDwere reported to be associated with CAD in an
international study and replicated in Koreans. However, the p values were between 7.9 x 10–4
and 1.3 x 10–3 when they were analyzed in Korean GWAS alone. That was why we did not
include these two SNPs in the current study. In addition, we excluded loci in BRAP, because
three SNPs at or near BRAPwere at 12q24, which was reported to be a pleiotropic region in
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recent studies [19, 20]. Such regions may affect multiple phenotypes and make it difficult to
clarify the independent effects in our study.
The association between the variants and the composite and individual component of major
adverse cardiac events (MACE), during a mean follow-up of 8.8 years, were analyzed.
Methods
Study population
BetweenNovember 2000, and March 2011, 2693 study subjects were enrolled from Cardiovas-
cular Genome Center, Yonsei University College of Medicine, Seoul, Korea. Men and women
with either history of, or more than two risk factors for CAD were recruited. Risk factors
included old age (men45 years; women55 years), history of hypertension (blood pressure
140/90 mmHg), diabetes mellitus (fasting blood glucose126 mg/dL or hemoglobinA1c
6.5%), hyperlipidemia (low-density lipoprotein-cholesterol130 mg/dL), and current
smoker. Trained nurses obtained the clinical data, including demographic parameters and
medical history. Patients underwent coronary angiography depending on the relevant chest
symptoms. CAD was defined as a significant stenosis (50%) in at least one epicardial coro-
nary artery. The Institutional ReviewBoard of SeveranceHospital, Yonsei University College
of Medicine approved all study designs and protocols, and all participants provided their writ-
ten informed consent.
Genotyping
Genomic DNA was extracted from the peripheral blood samples by QuickGene SNP Kit DNA
(Fuji film, Tokyo, Japan). Taqman genotyping was performed using ABI Prism 7000 (Applied
Biosystems, Foster City, CA, USA). Blind duplicates (10%) revealed a 99.6% genotyping con-
cordance rate, implying that a false discovery due to typing error was unlikely. The genotype
frequencies of two SNPs were all in agreement with the Hardy-Weinberg equilibrium test (p
>0.05).
Outcome variables
The outcome variables were MACE, which include cardiovascular death, non-fatal myocardial
infarction, coronary revascularization (percutaneous coronary intervention and coronary
artery bypass graft), and stroke. Death was classified as cardiovascular if it was related to myo-
cardial infarction or ischemia, arrhythmia, heart failure, or stroke. To assess MACE that
occurred between patients’ enrollment and December 31, 2012, computerized searches for the
cause of death were conducted using Korean National Health Insurance Corporation data.
OtherMACE were ascertained from bills with discharge diagnosis, of which nearly all are sub-
mitted to the Corporation. Prior Korean studies used this data to confirm long-term clinical
outcome [5, 21]. When an individual experiencedmultiple MACE during the entire follow-up
period, the first one was regarded as his or her MACE. The duration between the enrollment
and the first MACE was used in the survival analyses.
Statistical analysis
Continuous variables are presented as mean ± standard deviation and categorical variables are
presented as frequencies and percentages. Baseline characteristics of the study subjects accord-
ing to genotypes were compared by using analysis of variance for quantitative traits and the
chi-square test for categorical variables. Triglyceride levels that have a skewed distribution
were analyzed by Kruskal-Wallis test. Cumulative MACE-free survival curves for each
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genotype established by the Kaplan-Meier method were compared by the log-rank test. The
Cox proportional hazard regression analysis was used to identify independent predictors for
MACE and its individual components. Age, sex, and all available risk factors were adjusted for
in the multivariate analysis. When variables not significant in univariate analysis are excluded
in multivariate analysis, the model can be more informative. However, we included those vari-
ables by clinical reasoning, because they are known risk factors or confounders. In addition, we
could not rule out the possibility that they might be associated with biological pathways. There-
fore, we included the variables in multivariate analysis to control them. Hazard ratios and 95%
confidence intervals were reported. Adjustment for multiple testing was performed by using
Bonferroni correction.Our Bonferroni threshold was the α value divided by the number of
independent tests (0.05/2 = 0.025). The determinants of MACE were further analyzed in the
subgroups according to the history of CAD. All analyses used two-tailed tests with a signifi-
cance level of 0.05. All statistical analyses were performed using SAS 9.4 (SAS institute, Cary,
NC, USA).
Results
Characteristics of the study population
Out of 2693 patients (55.2 ± 11.0 years, male: 55.2%) enrolled in this study, 943 (35.0%) had
history of CAD. Most of the study subjects (98.3%) were hypertensive. Clinical characteristics
of the subjects classified based on the genotype of each SNP are displayed in Table 1. The fre-
quency of hyperlipidemia was different between the patients with each genotype of rs9508025
(p = 0.045), while the prevalence of CAD differ between the patients with each genotype of
rs1333049 (p<0.001).
Table 1. Baseline characteristics and clinical outcomes of the study population classified based on rs9508025 and rs1333049 genotype.
Total
(N = 2693)
rs9508025 (N = 2693) rs1333049 (N = 2675)
Variables GG
(N = 743)
CG
(N = 1316)
CC (N = 634) P value GG
(N = 718)
CG
(N = 1310)
CC (N = 647) P value
Age, years 55.2±11.0 54.8±11.1 55.4±10.9 55.3±11.3 0.48 55.4±11.3 55.2±11.0 55.1±10.8 0.87
Male 1486 (55.2) 418 (56.3) 717 (54.5) 351 (55.4) 0.74 337 (46.9) 580 (44.3) 280 (43.3) 0.35
Hypertension 2647 (98.3) 731 (98.4) 1291 (98.1) 625 (98.6) 0.73 706 (98.3) 1288 (98.3) 635 (98.2) 0.96
Diabetes mellitus 399 (14.8) 98 (13.2) 213 (16.2) 88 (13.9) 0.14 111 (15.5) 199 (15.2) 89 (13.8) 0.63
Hyperlipidemia 1111 (41.3) 309 (41.6) 516 (39.2) 286 (45.1) 0.045 297 (41.4) 544 (41.5) 263 (40.7) 0.93
Current smoker 391 (15.6) 102 (14.7) 186 (15.1) 103 (17.8) 0.27 106 (15.9) 197 (16.1) 86 (14.5) 0.66
CAD 943 (35.0) 249 (33.5) 472 (35.9) 222 (35.0) 0.56 243 (33.8) 424 (32.4) 268 (41.4) <0.001
BMI, kg/m2 25.0±3.0 25.1±3.1 24.9±3.0 24.9±2.9 0.66 25.0±2.8 25.0±3.1 24.8±3.0 0.57
Total cholesterol, mg/dL 197±43 197±46 196±41 197±42 0.72 196±45 197±40 196±44 0.94
Triglyceride, mg/dL 135 (101) 135 (96) 133 (100) 138 (109) 0.58 130 (99) 137 (101) 134 (99) 0.13
HDL-cholesterol, mg/dL 43.9±11.5 43.7±11.1 44.0±12.1 44.0±11.3 0.82 44.3±11.6 43.7±11.7 43.9±11.7 0.61
MACE 416 (15.4) 96 (12.9) 202 (15.4) 118 (18.6) 0.01 112 (15.6) 187 (14.3) 114 (17.6) 0.16
Cardiovascular death 21 (0.8) 5 (0.8) 8 (0.6) 7 (1.0) 0.50 6 (0.8) 11 (0.8) 4 (0.6) 0.86
Nonfatal MI 119 (4.4) 29 (3.9) 59 (4.5) 31 (4.9) 0.67 30 (4.2) 52 (4.0) 36 (5.6) 0.25
Coronary
revascularization
156 (5.8) 29 (3.9) 84 (6.4) 43 (6.8) 0.03 33 (4.6) 72 (5.5) 50 (7.7) 0.04
Nonfatal stroke 120 (4.5) 32 (4.3) 51 (3.9) 37 (5.8) 0.14 43 (6.0) 52 (4.0) 24 (3.7) 0.06
Data are presented as mean ± SD, median (interquartile range), or n (%); CAD, coronary artery disease; BMI, body mass index; HDL: high-density
lipoprotein; MACE, major adverse cardiovascular events; MI, myocardial infarction.
doi:10.1371/journal.pone.0164705.t001
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Association between the SNPs and cardiovascular events
During the mean follow-up of 8.8 years, 416 patients (15.4%) experiencedMACE: 21 cardio-
vascular death (0.8%), 119 non-fatal myocardial infarction (4.4%), 156 coronary revasculariza-
tion (5.8%), and 120 stroke (4.5%). The incidence of MACE was different between individuals
with each genotype of rs9508025 (12.9%, 15.4%, and 18.6% of patients with GG, GC, and CC
genotype, respectively, p = 0.01). No significant difference in MACE was found between sub-
jects with different rs1333049 genotypes (15.6%, 14.3%, and 17.6% of patients with GG, GC,
and CC genotype, respectively, p = 0.16).
Determinants of cardiovascular events
Fig 1A and 1B shows the Kaplan-Meier curves for MACE-free survival. The proportion was
significantly different among the individuals with different genotypes of rs9508025 (log rank
p = 0.02), but it was not significantly related to the genotype of rs1333049 (log rank p = 0.13).
Univariate and multivariate Cox proportional hazard analyses of the predictors of MACE are
presented in Table 2. Age, male sex, diabetes mellitus, hyperlipidemia, prior CAD, and C allele
of rs9508025 were associated with the higherMACE incidence. However, the genotype of
rs1333049 did not correlate with the outcomes. After adjusting for age, sex, and all available
risk factors, the rs9508025 variant was found to be a significantly associated with MACE (HR:
1.19, p = 0.02). Individual components of MACE were evaluated, and the results of multivariate
Cox regression analysis are shown in Table 3. Age, sex, hypertension, diabetes, hyperlipidemia,
smoking status, CAD, and the SNPs were included in the analysis. The association of the
rs9508025 variant with MACE was mainly due to its relation to coronary revascularization
Fig 1. Kaplan-Meier curves for long-term MACE-free survival of the study subjects depending on rs9508025 (A) and rs1333049
polymorphisms (B). The proportion was significantly different among the individuals with different genotypes of rs9508025 (log rank p = 0.015,
adjusted p = 0.020), but it was not significantly related to the genotype of rs1333049 (log rank p = 0.13, adjusted p = 0.26). Adjusted p values are
based on multivariate Cox proportional hazards regression analysis that included variables of age, sex, hypertension, diabetes mellitus,
hyperlipidemia, smoking status, CAD, and the SNPs.
doi:10.1371/journal.pone.0164705.g001
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(HR: 1.36, p = 0.02). Interestingly, the C allele of rs1333049 showed an association with the
incidence of coronary revascularization as well (HR: 1.34, p = 0.02) (Table 3).
CAD itself was associated with MACE and there seems to be an interaction among CAD,
MACE, and rs9508025.We analyzed the determinants of MACE in the subgroups classified by
the history of CAD, and found that the SNP was an independent determinant of MACE only in
patients with CAD (S1 Fig, S1 Table). It was not significant in patients without CAD (S1 Table).
rs1333049 did not show a significant association in both subgroups (S1 Fig and S1 Table).
Discussion
The major findings of this study are: 1) the C allele rs9508025 in FLT1 is significantly associ-
ated with a higherMACE rate, 2) the genotype of rs1333049 in 9p21 did not show an associa-
tion with the composite outcome, 3) the association of the rs9508025 variant with MACE was
mainly due to its relation to coronary revascularization,which was also associated with the
rs1333049 variant, 4) the association of rs9508025 was significant only in the subgroup with a
Table 2. Predictors of MACE determined by Cox regression analysis.
Univariate model Multivariate model
Factors HR (95% CI) P HR (95% CI) P
Age 1.04 (1.03–1.05) <0.001 1.03 (1.02–1.04) <0.001
Male 1.53 (1.25–1.87) <0.001 1.38 (1.09–1.73) 0.01
Hypertension 1.46 (0.61–3.52) 0.40 1.22 (0.50–3.00) 0.67
Diabetes Mellitus 2.08 (1.66–2.60) <0.001 1.51 (1.17–1.94) 0.002
Hyperlipidemia 1.76 (1.45–2.14) <0.001 1.19 (0.96–1.48) 0.11
Current smoker 1.10 (0.83–1.46) 0.50 1.07 (0.79–1.43) 0.66
CAD 2.92 (2.40–3.54) <0.001 2.00 (1.60–2.50) <0.001
rs9508025a 1.22 (1.07–1.39) 0.004 1.19 (1.03–1.38) 0.02
rs1333049a 1.07 (0.93–1.22) 0.34 1.09 (0.94–1.26) 0.26
MACE, major adverse cardiovascular events; HR, hazard ratio; CI, confidence interval; CAD, coronary artery disease.
aAdditive genetic model.
doi:10.1371/journal.pone.0164705.t002
Table 3. Predictors of the individual components of MACE in all patients (N = 2693).
MACE Cardiovascular death Nonfatal MI Coronary
revascularization
Nonfatal stroke
Factors HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Age 1.03 (1.02–1.04) < .001 1.06 (1.01–1.12) 0.02 1.01 (0.99–1.03) 0.41 1.02 (0.99–1.04) 0.10 1.06 (1.04–1.08) < .001
Male 1.38 (1.09–1.73) 0.01 3.61 (1.15–11.31) 0.002 2.13 (1.27–3.58) 0.004 1.38 (0.94–2.04) 0.10 0.91 (0.61–1.35) 0.64
Hypertension 1.22 (0.50–3.00) 0.67 NA NA 0.70 (0.17–2.88) 0.62 2.31 (0.32–16.7) 0.41 1.08 (0.27–4.43) 0.91
Diabetes mellitus 1.51 (1.17–1.94) 0.002 0.75 (0.22–2.63) 0.66 2.11 (1.32–3.36) 0.002 1.25 (0.81–1.91) 0.32 1.54 (0.96–2.46) 0.07
Hyperlipidemia 1.19 (0.96–1.48) 0.11 5.72 (1.84–17.73) 0.003 0.95 (0.62–1.47) 0.83 1.33 (0.92–1.93) 0.13 1.01 (0.68–1.50) 0.96
Current smoker 1.07 (0.79–1.43) 0.66 0.87 (0.24–3.11) 0.51 1.65 (1.02–2.67) 0.04 0.72 (0.42–1.25) 0.24 1.00 (0.55–1.81) 0.99
CAD 2.00 (1.60–2.50) < .001 1.21 (0.47–3.07) 0.69 2.43 (1.55–3.79) < .001 2.00 (1.60–2.50) < .001 0.75 (0.49–1.17) 0.21
rs9508025a 1.19 (1.03–1.38) 0.02 1.17 (0.62–2.18) 0.63 0.97 (0.73–1.31) 0.86 1.36 (1.06–1.75) 0.02 1.23 (0.95–1.60) 0.11
rs1333049a 1.09 (0.94–1.26) 0.26 0.93 (0.49–1.77) 0.82 1.21 (0.90–1.61) 0.21 1.34 (1.04–1.72) 0.02 0.81 (0.62–1.06) 0.12
MACE, major adverse cardiac events; MI, myocardial infarction; HR, hazard ratio; CI, confidence internal; CAD, coronary artery disease; NA, not available
due to missing data.
aAdditive genetic model.
doi:10.1371/journal.pone.0164705.t003
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history of CAD. The strengths of our study are as follows 1) this study is the first to show the
association between an FLT1 variant and the long-term cardiovascular outcome, 2) we verified
the influence of the variant identified in a prior GWAS in Asians, a less-studied ethnicity, 3) to
the best of our knowledge, this is one of the largest studies with the longest follow-up evaluat-
ing the cardiovascular outcome, 4) in contrast with the prior studies, looking into the individ-
ual components of MACE has helped us understand the relation between the variants and
specific complications. Our results may provide a novel genomic marker for atherosclerotic
cardiovascular disease.
In the current study, we demonstrated the association between rs9508025, a FLT1 variant
and cardiovascular risk, not using case-control design but analyzing clinical follow-up data. To
date, studies of the variants in FLT1 have been conductedmostly in non-cardiovascular dis-
eases. Several SNPs were associated with nephropathy [22], macular degeneration [23],
obstructive pulmonary disease [24], cancers [24–26], and the response to anti-cancer therapy
[27]. Conversely, studies that investigated relationships between the variants of FLT1 and CAD
are extremely limited. An association between rs931428 of FLT1 and CADwas discovered in
the study by CARDIoGRAMplusC4D Consortium [5], in which a large part of the participants
were of European descendants. This marker was recently confirmed in Japanese reports [28].
However, those studies did not find an association between rs9508025, the marker in the cur-
rent study, with CAD. Due to this disparity among different populations, the value of our
marker on cardiovascular outcomes may not be directly applicable to other populations. The
risk allele shown in the current study was a C allele that was associated with an increased risk
of CAD in our prior report [18]. That report showed the risk analyzed by GWAS and replica-
tion by using data of CAD patients and controls. Meanwhile, the present study analyzed the
long-term cardiovascular risk. Although long-term outcome is a rather larger concept than
CAD risk, we can tell that the directionality of the association between the risk allele and the
phenotype is the same. Particularly, many events demanding coronary revascularization are
related to the progression of CAD in the same or other coronary arteries [29].
The mechanism underlying the association between FLT1 variant and CAD or MACE is
not fully understood yet. It was reported that a relationship exists between soluble Flt-1, coded
by that gene, and mortality in chronic kidney disease patients [30], but the data have been
insufficient to explain its biological effect. A variant of rs9319428 in FLT1 revealed an associa-
tion with diastolic blood pressure [31], however, in our current study, the relationship between
rs9508025 variants and blood pressure was not found to be significant (data not shown). A
functional analysis of pathways of genes associated with CAD showed that FLT1 belongs to the
clusters of genes coding proteins involved in focal adhesion and extracellularmatrix interac-
tions [32]. In atherosclerotic cardiovascular disease, ischemic episodes are critically influenced
by collateral circulation rather than atheroma burden only [33]. Therefore, it cannot be ruled
out that FLT1 codes a protein that plays a role in angiogenesis and vascular development [34],
which influence cardiovascular risk. Our results showed that a FLT1 variant (rs9508025) was
related to the incidence of coronary revascularization.The occurrence of revascularization
depends on many factors, including the progression of arterial stenosis, thrombotic events, and
even physician’s discretion. Therefore, it is difficult to explain, using our current data, how this
variant was linked to the rate of revascularization.
Ever since it was first reported in 2007, the association between 9p21 and CAD risk has
been steadily replicated in various ethnicities [5]. In addition, the significance of several SNPs
in 9p21, such as rs1333049, rs2383206, and rs10757278 were validated in East Asians as well
[15]. Although our data showed that the C allele of rs1333049 correlates with the baseline CAD
risk, the association of this SNP was not significant for the long-term outcomes. Studies of the
influence of variants in 9p21 on the clinical outcomes have been limited, and their results were
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inconsistent. Thus, it seems premature to come to any conclusion about the relationship
between this locus and the long-term cardiovascular outcomes. In the studies performed in
Germany [35], China [16], New Zealand [36], or USA [37], rs1333049 was not found to be
associated with total mortality or cardiovascular events. On the contrary, this SNP was linked
to the incidence of cardiovascular diseases in the Bruneck study with a longer follow-up [38].
Similar finding has also been observed in the MORGAM project [12]. In general, however,
most of the studies did not follow up the patients sufficiently long, and the cardiovascular
events were not analyzed in detail according to the individual components. We analyzed the
association between each SNP and the individual components of MACE, and determined that
a variant of rs1333049 correlates with the incidence of coronary revascularization.This finding
may be in accordance with previous studies that showed associations between 9p21 variants
and the CAD burden [39, 40] or the progression of coronary atherosclerosis [41].
This study has several potential limitations in addition to its strengths. We analyzed the
effects of two SNPs selected based on a prior GWAS. Evaluation of more loci may have pro-
vided us with additional information about their association with cardiovascular events. Fur-
thermore, data on pharmacological or non-pharmacological treatments were not available in
this study. Therefore, we cannot fully rule out the possible influences of those therapeutic fac-
tors. However, the frequencies of risk factors were similar between the individuals with differ-
ent genotypes, so the difference in treatments between different groups may have been small.
In addition, statistical significance of our findings after correctionmay not be sufficiently
strong. Also, p-values were not corrected for the number of traits tested and should be inter-
preted with caution.
Conclusions
In conclusion, rs9508025 in FLT1 was significantly associated with long-term cardiovascular
events, particularly in patients with CAD. This relationship was mainly due to its influence on
coronary revascularization.The association of rs1333049 in 9p21 with the outcome was not
significant, although this variant was also linked to the risk of coronary revascularization.
Supporting Information
S1 Fig. Kaplan-Meier curves for the long-termMACE-free survival in the subgroup with
CAD according to the rs9508025 (A) and rs1333049 polymorphisms (B). The impact of
rs9508025 on MACE was evident in the subgroup with CAD, whereas rs1333049 did not show
significant effect.
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S1 Table. Predictors of the individual components of MACE in patients with or without
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